



Addendum

Addendum. 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1): S89–S97 *American Diabetes Association*

<https://doi.org/10.2337/dc20-ad08b>

Section 8, Obesity Management for the Treatment of Type 2 Diabetes, of the *Standards of Medical Care in Diabetes—2020* has been annotated based on a U.S. Food and Drug Administration Drug Safety Communication.

The online version of the article (<https://doi.org/10.2337/dc20-S008>) reflects the changes described below.

Updates have been made to the “Approved Weight-Loss Medications” subsection (p. S92).

The following sentence was revised to change “Five” to “Four”:

“Four weight-loss medications are FDA approved for long-term use (more than a few weeks) by patients with BMI ≥ 27 kg/m² with one or more obesity-associated comorbid condition (e.g., type 2 diabetes, hypertension, and/or dyslipidemia) who are motivated to lose weight (46).”

The following sentence was added:

“The FDA requested the withdrawal of weight-loss drug lorcaserin (U.S. Food and Drug Administration, 2020); it should no longer be used.”

Table 8.2:

“Lorcaserin” has been removed from Table 8.2.

Reference

U.S. Food and Drug Administration. FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market. Potential risk of cancer outweighs the benefits. 13 February 2020 [FDA Drug Safety Communication]. Available from <https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market>